The 20-minute tirzepatide provider verification

Why verification falls on you in this category

With brand medication, the FDA reviewed the product, the manufacturer runs pharmacovigilance, and the dispensing pharmacy operates inside a chain of custody built over a century. With compounded medication, the finished product was never FDA-reviewed — the quality controls that exist are the pharmacy's licensure, the 503A/503B framework, and the program's clinical practices. Since the shortage's resolution narrowed legal compounding to personalization pathways, the gap between careful programs and opportunists has widened, and the counterfeit market that grew during the shortage hasn't vanished. Twenty minutes of checking is the entire due-diligence budget this category asks of you; spend it.

Green flags vs red flags, side by side

Any single red flag is disqualifying in our scoring system — legitimate programs pass all six checkpoints without friction.

The twenty-minute verification, in order

Minute 0–5: ask the program to name its pharmacy in writing; refusal ends the process. Minute 5–10: look the pharmacy up on its state board of pharmacy license search, and if it claims 503B status, confirm it on the FDA's registered outsourcing facility list. Minute 10–13: check the telehealth platform for LegitScript certification and a physical address. Minute 13–17: read the refund and cancellation policy end to end — for prepaid plans, this document is worth more than the pricing page. Minute 17–20: send one pre-sales question to support and note the response time and quality; it's the best available preview of what post-sales support will be. Our printable checklist packages the whole sequence.

Understanding 503A vs 503B in two minutes

The pharmacy's regulatory letter matters more than its marketing. A 503A pharmacy is a state-licensed compounding pharmacy that prepares patient-specific prescriptions; oversight is primarily the state board's, and quality rests on that pharmacy's own practices. A 503B outsourcing facility registers with the FDA, is subject to FDA inspection and current good manufacturing practice requirements, and can compound at scale — generally the stronger quality posture for a nationwide telehealth program. Neither letter makes a product FDA-approved, and a diligent 503A can outperform a sloppy 503B, but when a program tells you which it uses, you've learned two things: the applicable oversight regime, and the fact that the program answers structural questions at all. Our 503A vs 503B explainer goes deeper on the differences.

How the tracked providers score on safety signals

The chart combines the two safety-adjacent components of our 100-point rubric — pharmacy transparency (20 points) and terms clarity (15 points). NexLife leads at 30/35 on the strength of named-pharmacy disclosure and published plan terms; the rest of the field clusters at 22–26, generally losing points on pre-payment pharmacy naming. No tracked provider triggers a disqualifying red flag — the disqualifiers live in the untracked corners of this market, which is precisely why they're untracked.

If something goes wrong anyway

Report product problems to your prescriber first — dosing confusion, unexpected reactions, or product appearance issues are clinical events before they're consumer complaints. The FDA's MedWatch program accepts adverse-event reports for compounded products, and state boards of pharmacy accept complaints against licensed pharmacies. Keep the vial, packaging, and lot information. And tell the program: in our experience, response-to-failure is the single most revealing provider behavior — it's why negative-review reply rates carry real weight in our scoring system, and why a 100% reply rate is worth more than a tenth of a rating point.